期刊文献+

成年型烟雾病患者血管内皮生长因子和基质金属蛋白酶-9血清水平与Suzuki分级的关系 被引量:8

Relationship between serum levels of vascular endothelial growth factor and matrix metalloproteinase-9 and Suzuki' s grading in adult moyamoya disease
原文传递
导出
摘要 目的探讨成年型烟雾病(moyamoya disease,MMD)患者血管内皮生长因子(vascular endothelial growth factor,VEGF)和基质金属蛋白酶-9(matrix metalloproteinase-9,MMP-9)血清水平及其与Suzuki分级的关系。方法从南京卒中注册系统中提取2009年4月至2011年1月间以短暂性脑缺血发作或首发卒中的52例住院或门诊复诊的成年型MMD患者。同时选取16名性别和年龄与MMD患者相配匹的健康人作为对照组。通过酶联免疫吸附分析法,比较MMD患者VEGF和MMP-9血清水平与健康对照人群间的差异;根据Suzuki6级分级标准,将MMD患者分为不同亚组,分别分析不同亚组VEGF和MMP-9血清水平与Suzuki分级的相关性;另外,对MMD患者VEGF和MMP-9血清水平的相关性亦作了分析。结果缺血型和出血型MMD患者VEGF血清水平分别为(289.4±69.2)pg/ml和(324.3±95.6)pg/ml,均高于健康对照组[(63.5±7.6)pg/ml;F=69.43;P〈0.01];缺血型和出血型MMD患者MMP-9血清水平分别为(499.4±76.2)ng/ml和(531.2±100.2)ng/ml,亦均高于健康对照组[(257.1±30.7)ng/ml;F=66.023;P〈0.01]。随着Suzuki分级的升高,VEGF和MMP-9血清水平呈现升高趋势,相关系数r分别为0.879(P〈0.01)和0.838(P〈0.01)。另外,VEGF和MMP-9之间存在正向线性相关(r=0.590,P〈0.01)。结论成年型MMD患者VEGF和MMP-9血清水平高于健康人群,提示参与了血管新生;随着患者病情的进展,VEGF和MMP-9血清水平呈现升高趋势,提示VEGF和MMP-9血清水平能反映患者的病变严重程度。 Objective To investigate the relationship between serum levels of vascular endothelial growth factor ( VEGF ) and matrix rnetalloproteinase-9 ( MMP-9 ) and Suzuki' s grading system in adult moyamoya disease (MMD). Methods Fifty-two adult patients with MMD, who were diagnosed in Jinling hospital between April 2009 and January 2010, were retrieved from the Nanjing Stroke Registry Program (NSRP). Sixteen sex- and age-matched healthy individuals with MMD patients consisted of the control group. Using enzyme-linked immunosorbent assay, serum concentrations of VEGF and MMP-9 were compared between adult MMD patients and healthy individuals. By Suzuki' s six-grading system, patients were divided into different subgroups, and the correlation of serum levels of VEGF and MMP-9 corresponding to different subgroup and Suzuki' s grading was respectively analyzed. In addition, the correlation of serum levels of VEGF and MMP-9 was also evaluated. Results Serum VEGF concentrations in isehemie and hemorrhagic MMD patients was respectively ( 289.4± 69. 2 ) pg/ml and ( 324. 3 ± 95.6 ) pg/ml and were significantly higher compared to those in healthy controls ( 63.5 ± 7.6 ) pg./ml ; F = 69.43, P 〈 0. 01 ).Similar findings were observed for MMP-9 ( (499.4 ± 76. 2) ng/ml and (531.2 ± 100. 2) ng/ml versus (257. 1 ± 30. 7) ng/ml; F = 66. 023,P 〈 0. 01 ). With the increase of Suzuki' s grading, serum levels of VEGF and MMP-9 respectively showed a high trend (r = 0. 879, P 〈 0. 01 ; r = 0. 838, P 〈 0. 01 ). In addition, a positive correlation between serum levels of VEGF and MMP-9 was found in the MMD group( r = 0. 590, P 〈 0. 01 ). Conclusion The results show that serum levels of VEGF and MMP-9 in adult MMD are higher than those in healthy controls, which may play a role in neovascularization in MMD, and moreover, serum levels of VEGF and MMP-9 show a high trend with the progression of MMD, which suggest that serum levels of VEGF and MMP-9 can reflect the severity of MMD.
出处 《中华神经科杂志》 CAS CSCD 北大核心 2012年第6期404-408,共5页 Chinese Journal of Neurology
基金 江苏省自然科学基金(重点项目)资助(BK2010067)
关键词 脑底异常血管网病 卒中 血管内皮生长因子 基质金属蛋白酶9 疾病严重 程度指数 Moyamoya disease Stroke Vascular endothelial growth factor Matrix metalloproteinase 9 Severity of illness index
  • 相关文献

参考文献20

  • 1Suzuki J, Takaku A. Cerebrovascular " moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol, 1969, 20: 288-299.
  • 2Kim JM, Lee SH, Roh JK. Changing ischaemic lesion patterns in adult moyamoya disease. J Neurol Neurosurg Psychiatry, 2009, 80 : 36-40.
  • 3Liu W, Zhu S, Wang X, et al. Evaluation of angiographic changes of the anterior choroidal and posterior communicating arteries for predicting cerebrovascular lesions in adult moyamoya disease. J Clin Neurosci, 2011, 18:374-378.
  • 4刘文华,岳炫烨,王笑亮,周志明,朱双根,马驰原,王汉东,朱武生,徐格林,刘新峰.出血型烟雾病患者72例的损伤模式[J].中华神经科杂志,2011,44(1):34-37. 被引量:19
  • 5刘文华,朱双根,王笑亮,岳炫烨,周志明,殷勤,张仁良,徐格林,刘新峰.成年型烟雾病缺血损伤模式与Suzuki分级的关系[J].中华神经科杂志,2010,43(6):403-407. 被引量:13
  • 6刘文华,倪冠中,黄显军,孙文,朱武生,徐格林,刘新峰.成年型烟雾病侧支循环的分布模式[J].中华神经科杂志,2012,45(3):149-153. 被引量:21
  • 7Rafat N, Beck GCh, Pena-Tapia PG, et al. Increased levels of circulating endothelial progenitor cells in patients with Moyamoya disease. Stroke, 2009, 40:432-438.
  • 8Jung KH, Chu K, Lee ST, et al. Circulating endothelial progenitor cells as a pathogenetic marker of moyamoya disease. J Cereb Blood Flow Metab, 2008, 28 : 1795-1803.
  • 9Yoshihara T, Taguchi A, Matsuyama T, et al. Increase in circulating CD34-positive cells in patients with angiographic evidence of moyamoya-like vessels. J Cereb Blood Flow Metab, 2008, 28:1086-1089.
  • 10Huang PH, Chen YH, Wang CH, et al. Matrix metalloproteinase- 9 is essential for ischemia-induced neovascularization by modulating bone marrow-derived endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2009. 29 : 1179-1184.

二级参考文献35

  • 1Kuroda S,Houkin K.Moyamoya disease:current concepts and future perspectives.Lancet Neurol,2008,7:1056-1066.
  • 2Fukui M,Kono S,Sueishi K,et al.Moyamoya disease.Neuropathology,2000,20:61-64.
  • 3Mugikura S,Takahashi S,Higano S,et al.The relationship between cerebral infarction and angiographic characteristics in childhood moyamoya disease.AJNR Am J Neuroradiol,1999,20:336-343.
  • 4Liu X,Xu G,Wu W,et al.Subtypes and one-year survival of first-ever stroke in Chinese patients:The Nanjing Stroke Registry.Cerebrovasc Dis,2006,22:130-136.
  • 5Fukui M.Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis ('moyamoya' disease).Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) of the Ministry of Health and Welfare,Japan.Clin Neurol Neurosurg,1997,2:238-240.
  • 6Scott RM,Smith ER.Moyamoya disease and moyamoya syndrome.N Engl J Med,2009,360:1226-1237.
  • 7Kim JM,Lee SH,Roh JK.Changing ischaemic lesion patterns in adult moyamoya disease.J Neurol Neurosurg Psychiatry,2009,80:36-40.
  • 8Suzuki J,Kodama N.Moyamoya disease--a review.Stroke,1983,14:104-109.
  • 9Fujiwara H,Momoshima S,Kuribayashi S.Leptomeningeal high signal intensity (ivy sign) on fluid-attenuated inversion-recovery (FLAIR) MR images in moyamoya disease.Eur J Radiol,2005,55:224-230.
  • 10Mori N,Mugikura S,Higano S,et al.The leptomeningeal "ivy sign" on fluid-attenuated inversion recovery MR imaging in Moyamoya disease:a sign of decreased cerebral vascular reserve? AJNR Am J Neuroradiol,2009,30:930-935.

共引文献45

同被引文献99

  • 1杨秀军,彭仁罗.脑动脉瘤磁共振血管成像与脑血管造影对照研究[J].中华放射学杂志,1996,30(7):456-459. 被引量:11
  • 2Kuroda S, Houkin K. Moyamoya disease: current concepts and future perspectives. Lancet Neurol, 2008, 7: 1056-1066.
  • 3Ikeda H, Sasaki T, Yoshimoto T, et al. Mapping of a familial moyamoya disease gene to chromosome 3p24.2-p26. Am J Hum Genet, 1999, 64: 533-537.
  • 4Sakurai K, ttoriuchi , Ikeda H, et al. A novel susceptibility locus for moyamoya disease on chromosome 8q23. J Hum Genet, 2004, 49 : 278-281.
  • 5Roder C, Peters V, Kasuya H, et al. Polymorphisms in TGFBI and PDGFRB are associated with Moyamoya disease in European patients. Acta Neurochir (Wien), 2010, 152: 2153-2160.
  • 6Liu W, Hashikata H, Inoue K, et al. A rare Asian founder polymorphism of Raptor may explain the high prevalence of Moyamoya disease among East Asians and its low prevalence among Caucasians. Environ Health Prev Med, 2010, 15: 94- 104.
  • 7Li H, Zhang ZS, Liu W, et al. Association of a functional polymorphism in the MMP-3 gene with Moyamoya Disease in the Chinese Han population. Cerebrovasc Dis, 2010, 30 : 6184525.
  • 8Liu W, Morito D, Takashima S, et al. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One, 2011, 6: e22542.
  • 9Miyawaki S, Imai H, Takayanagi S, et al. Identification of a genetic variant common to moyamoya disease and intracranial major artery stenosis/occlusion. Stroke, 2012, 43 : 3371-3374.
  • 10Kamada F', Aoki Y, Narisawa A, et al. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet, 2011, 56: 34-40.

引证文献8

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部